Clinical trial
Phase 1/2, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease (AURORA)
NCT07439887 is registered in ClinicalTrials.gov with Ray Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2, Open-Label, Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease (AURORA)
- Lead sponsor
- Ray Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- January 28, 2026
- Completion date
- December 1, 2030
- Enrollment
- 18 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.